Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Pexidartinib in Advanced Pancreatic or Colorectal Cancers
NCT02777710Phase 1Completed
- Sponsor
- Centre Léon Bérard
- Start
- Jun 2016
- Primary completion
- Nov 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of pexidartinib in pancreatic cancer (PC) and colorectal cancer (CRC), sponsored by Centre Léon Bérard. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Jun 2016; status: completed.
02
Drugs
pexidartinib
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02777710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02777710.